Article info

Download PDFPDF
Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

Authors

  1. Address correspondence and reprint requests to Domenica Lorusso, MD, Department of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy. E-mail: kettalorusso{at}libero.it.

Citation

Di Legge A, Trivellizzi IN, Moruzzi MC, et al
Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

Publication history

  • Received March 31, 2011
  • First published November 1, 2011.
Online issue publication 
November 01, 2011

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.